31737-09-4

Basic information

• Product Name: 6-CHLORO-1-METHYLURACIL
• Synonyms: 6-CHLORO-1-METHYLURACIL;6-Chloro-1-methylpyrimidine-2,4(1H,3H)-dione
• CAS NO: 31737-09-4
• Molecular Formula: C₅H₅ClN₂O₂
• Molecular Weight: 160.56
• Mol File: 31737-09-4.mol

Chemical Properties

• Melting Point: 186 °C
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.51g/cm³
• Refractive Index: 1.58
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 8.36±0.40(Predicted)
• CAS DataBase Reference: 6-CHLORO-1-METHYLURACIL(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-1-METHYLURACIL(31737-09-4)
• EPA Substance Registry System: 6-CHLORO-1-METHYLURACIL(31737-09-4)

Safety Data

• Hazardous Substances Data: 31737-09-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
6-Chloro-1-methyluracil is used as a key intermediate in the synthesis of alloxazine 5-oxides and fervenulin 4-oxides. These compounds are of interest in the pharmaceutical industry due to their potential applications in the development of new drugs.
Used in Chemical Research:
In the field of chemical research, 6-chloro-1-methyluracil serves as a valuable starting material for the development of new syntheses and the exploration of novel chemical reactions. Its unique structure allows for further functionalization and modification, leading to the creation of new compounds with potential applications in various industries.
Used in the Synthesis of Alloxazine 5-oxides:
6-Chloro-1-methyluracil is used as a starting material for the synthesis of alloxazine 5-oxides, which are important compounds in the development of pharmaceuticals. The application reason for using 6-CHLORO-1-METHYLURACIL in this synthesis is its unique structure, which allows for the formation of the desired alloxazine 5-oxides through nitrative cyclization.
Used in the Synthesis of Fervenulin 4-oxides:
Similarly, 6-chloro-1-methyluracil is also used in the synthesis of fervenulin 4-oxides, another class of compounds with potential pharmaceutical applications. 6-CHLORO-1-METHYLURACIL's structure enables the formation of fervenulin 4-oxides through a similar nitrative cyclization process, making it a valuable intermediate in this synthesis pathway.

InChI:InChI=1/C5H5ClN2O2/c1-8-3(6)2-4(9)7-5(8)10/h2H,1H3,(H,7,9,10)

Upstream product

• 4270-27-3 6-chlorouracil 
• 74-88-4 methyl iodide 
• 1188497-82-6 C₆H₅ClN₂O₃ 
• 89-25-8 edaravone 

Downstream Products

• 183006-43-1 6-(3-chloro-4-fluoroanilino)-1-methyluracil 
• 89465-16-7 1-methyl-6-methylamino-1H-pyrimidine-2,4-dione 
• 193196-41-7 6-benzylthio-1-methyluracil 
• 42542-57-4 1-methyl-6-phenyl-2,4(1H,3H)-pyrimidinedione 
• 1797409-07-4 6-(dimethylamino)-1-methylpyrimidine-2,4(1H,3H)-dione 

Relevant articles and documents

A novel synthesis of fused uracils: Indenopyrimidopyridazines, pyrimidopyridazines, and pyrazolopyrimidines for antimicrobial and antitumor evalution

A variety of different compounds of fused uracils were prepared simply by the heating of 6-hydrazinyl-1-methyl-, 6-hydrazinyl-1-propyl-, or 6-hydrazinyl-1,3-dipropyluracil under reflux with ninhydrin, isatin, benzylidene malononitrile, benzylylidene ethyl cyanoacetate, benzil, and phenacyl bromide derivatives. The newly synthesized compounds were completely screened for antimicrobial and antitumor activity.

PYRIMIDONE COMPOUNDS USED AS LP-PLA2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREOF

The present invention relates to pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof. The structure of the pyrimidone compounds is represented by general formula (I), wherein R1, R2, Rs

Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is considered to be a promising therapeutic target for several inflammation-associated diseases. Herein, we describe the discovery of a series of pyrimidone derivatives as Lp-PLA2 inhibitors. Systematic structural modifications led to the identification of several pyrimidone compounds with promising in vitro inhibitory potency and pharmacokinetic properties. Compound 14c, selected for in vivo evaluation, demonstrated decent pharmacokinetic profiles and robust inhibitory potency against Lp-PLA2 in Sprague-Dawley (SD) rats. Furthermore, 14c significantly inhibited retinal thickening in STZ-induced diabetic SD rats as a model of diabetic macular edema (DME) after oral dosing for 4 weeks. Taken together, these results suggested that 14c can serve as a valuable lead in the search for new Lp-PLA2 inhibitors for prevention and/or treatment of DME.

Uracil derivatives, its preparation method and application thereof

The invention relates to a uracil derivative shown as a general formula I, salt thereof acceptable in pharmacy, a solvate thereof and a solvate of the salt thereof acceptable in pharmacy. The invention also relates to a preparation method of the uracil derivative and an application thereof as a therapeutic agent, particularly a dipeptidyl peptidase-IV (DDP-IV) inhibitor.

A mild and efficient method for the deformylation of 5-formyl uracils and synthesis of 4,4￠-methylidenebis(1-phenyl-3-methyl-5-pyrazolone)

6-Substituted 5-formyl uracils undergo an interesting reaction with 1-phenyl-3-methyl-5-pyrazolone in the presence of base catalyst to afford deformylated uracils and 4,4￠-methylidenebis(1-phenyl-3-methyl-5- pyrazolone) in excellent yields. Georg Thieme V

Purines XIV. [1]. Reactivity of 8-Bromo-3,9-dimethylxanthine Towards Some Nucleophilic Reagents

The reactivity of 8-bromo-3,9-dimethylxanthine (6) towards a variety of nucleophilic reagents has been investigated. Nucleophilic displacements take place easily with aliphatic mercaptans and aliphatic alcohols, whereas aliphatic amines required more severe conditions. Prolonged heating of 6 with amines causes a new type of rearrangement from 3,9- to 3,7-dimethylxanthines due to a 1,3-sigmatropic shift of the N(9)-methyl group.